<?xml version='1.0' encoding='utf-8'?>
<document id="26736984"><sentence text="Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole."><entity charOffset="44-55" id="DDI-PubMed.26736984.s1.e0" text="simvastatin" /><entity charOffset="70-82" id="DDI-PubMed.26736984.s1.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.26736984.s1.e0" e2="DDI-PubMed.26736984.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26736984.s1.e0" e2="DDI-PubMed.26736984.s1.e1" /></sentence><sentence text="Concomitant use of simvastatin, a HMG-CoA reductase inhibitor, with a potent CYP3A4 inhibitor, itraconazole, can result in a serious drug-drug interaction induced severe adverse event, rhabdomyolysis"><entity charOffset="19-30" id="DDI-PubMed.26736984.s2.e0" text="simvastatin" /><entity charOffset="95-107" id="DDI-PubMed.26736984.s2.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.26736984.s2.e0" e2="DDI-PubMed.26736984.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26736984.s2.e0" e2="DDI-PubMed.26736984.s2.e1" /></sentence><sentence text=" Even though pharmacokinetic data regarding such interaction are available, they cannot be used for quantitative prediction" /><sentence text=" For this reason, we aimed to develop a pharmacokinetic model for predicting the magnitude of inhibition of simvastatin metabolism by itraconazole"><entity charOffset="108-119" id="DDI-PubMed.26736984.s4.e0" text="simvastatin" /><entity charOffset="134-146" id="DDI-PubMed.26736984.s4.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.26736984.s4.e0" e2="DDI-PubMed.26736984.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26736984.s4.e0" e2="DDI-PubMed.26736984.s4.e1" /></sentence><sentence text="" /><sentence text="Published data involving pharmacokinetic of simvastatin, itraconazole, and pharmacokinetic interaction between simvastatin and itraconazole were selected from PubMed search"><entity charOffset="44-55" id="DDI-PubMed.26736984.s6.e0" text="simvastatin" /><entity charOffset="57-69" id="DDI-PubMed.26736984.s6.e1" text="itraconazole" /><entity charOffset="111-122" id="DDI-PubMed.26736984.s6.e2" text="simvastatin" /><entity charOffset="127-139" id="DDI-PubMed.26736984.s6.e3" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.26736984.s6.e0" e2="DDI-PubMed.26736984.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26736984.s6.e0" e2="DDI-PubMed.26736984.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26736984.s6.e0" e2="DDI-PubMed.26736984.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26736984.s6.e0" e2="DDI-PubMed.26736984.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26736984.s6.e1" e2="DDI-PubMed.26736984.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26736984.s6.e1" e2="DDI-PubMed.26736984.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26736984.s6.e1" e2="DDI-PubMed.26736984.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26736984.s6.e2" e2="DDI-PubMed.26736984.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26736984.s6.e2" e2="DDI-PubMed.26736984.s6.e3" /></sentence><sentence text=" Serum simvastatin concentrations were subsequently extracted and used for model development"><entity charOffset="7-18" id="DDI-PubMed.26736984.s7.e0" text="simvastatin" /></sentence><sentence text=" Advanced Continuous Simulating Language Extreme (ACSLX) was used for modeling" /><sentence text="" /><sentence text="The drug-drug interaction model between simvastatin and itraconazole was simultaneously modeled using a one compartment parent-metabolite model for simvastatin, and a two-compartment model for itraconazole"><entity charOffset="40-51" id="DDI-PubMed.26736984.s10.e0" text="simvastatin" /><entity charOffset="56-68" id="DDI-PubMed.26736984.s10.e1" text="itraconazole" /><entity charOffset="148-159" id="DDI-PubMed.26736984.s10.e2" text="simvastatin" /><entity charOffset="193-205" id="DDI-PubMed.26736984.s10.e3" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.26736984.s10.e0" e2="DDI-PubMed.26736984.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26736984.s10.e0" e2="DDI-PubMed.26736984.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26736984.s10.e0" e2="DDI-PubMed.26736984.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26736984.s10.e0" e2="DDI-PubMed.26736984.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26736984.s10.e1" e2="DDI-PubMed.26736984.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26736984.s10.e1" e2="DDI-PubMed.26736984.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26736984.s10.e1" e2="DDI-PubMed.26736984.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26736984.s10.e2" e2="DDI-PubMed.26736984.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26736984.s10.e2" e2="DDI-PubMed.26736984.s10.e3" /></sentence><sentence text="" /><sentence text="The final drug-drug interaction model can adequately describe the actual simvastatin concentrations"><entity charOffset="73-84" id="DDI-PubMed.26736984.s12.e0" text="simvastatin" /></sentence><sentence text=" Model application can be of advantage for dosing adjustment to avoid serious adverse effects resulted from concomitant use of both drugs" /><sentence text="" /></document>